Transcriptional Regulation of Tumour Necrosis Factor-related Apoptosis-inducing Ligand

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2013 Jan 19

PMID 23329170

Citations 9

Authors

Nor Saadah M Azahri

Mary M Kavurma

Affiliations

Soon will be listed here.

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has dual functions mediating both apoptosis and survival of cells. This review focusses on the current regulatory factors that control TRAIL transcription. Here, we also highlight the role of distinct transcription factors that co-operate and regulate TRAIL in different pathological states. A better understanding of the molecular signalling pathways of TRAIL-induced cell death and survival in disease may lead to more sophisticated technologies for novel therapeutic targets.

Citing Articles

Immunomodulatory Functions of TNF-Related Apoptosis-Inducing Ligand in Type 1 Diabetes.

Fogarasi M, Dima S Cells. 2024; 13(20.

PMID: 39451194 PMC: 11506310. DOI: 10.3390/cells13201676.

The generation of stable microvessels in ischemia is mediated by endothelial cell derived TRAIL.

Cartland S, Patil M, Kelland E, Le N, Boccanfuso L, Stanley C Sci Adv. 2024; 10(40):eadn8760.

PMID: 39365855 PMC: 11451529. DOI: 10.1126/sciadv.adn8760.

Tumor necrosis factor‑related apoptosis‑inducing ligand is a novel transcriptional target of runt‑related transcription factor 1.

Yoshida T, Yamasaki K, Tadagaki K, Kuwahara Y, Matsumoto A, Sofovic A Int J Oncol. 2021; 60(1).

PMID: 34958111 PMC: 8727134. DOI: 10.3892/ijo.2021.5296.

TRAIL signals, extracellular matrix and vessel remodelling.

Patil M, Cartland S, Kavurma M Vasc Biol. 2020; 2(1):R73-R84.

PMID: 32923976 PMC: 7439926. DOI: 10.1530/VB-20-0005.

Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.

Cartland S, Harith H, Genner S, Dang L, Cogger V, Vellozzi M Sci Rep. 2017; 7(1):1898.

PMID: 28507343 PMC: 5432513. DOI: 10.1038/s41598-017-01721-4.

References

Santini M, Talora C, Seki T, Bolgan L, Dotto G . Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci U S A. 2001; 98(17):9575-80. PMC: 55494. DOI: 10.1073/pnas.161299698. View

Fanger N, Maliszewski C, Schooley K, Griffith T . Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med. 1999; 190(8):1155-64. PMC: 2195665. DOI: 10.1084/jem.190.8.1155. View

Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D . Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005; 280(49):40599-608. DOI: 10.1074/jbc.M509560200. View

Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H . TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res. 2007; 26(6B):4115-24. View

Stark G, Kerr I, Williams B, Silverman R, Schreiber R . How cells respond to interferons. Annu Rev Biochem. 1998; 67:227-64. DOI: 10.1146/annurev.biochem.67.1.227. View

Di Bartolo B, Chan J, Bennett M, Cartland S, Bao S, Tuch B . TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe ⁻/⁻ mice. Diabetologia. 2011; 54(12):3157-67. DOI: 10.1007/s00125-011-2308-0. View

Woods D, Alvarez C, Johnson A . Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. Gynecol Oncol. 2008; 108(3):632-40. DOI: 10.1016/j.ygyno.2007.11.034. View

Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes P, Dicker D . TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther. 2008; 7(12):2034-8. DOI: 10.4161/cbt.7.12.7460. View

Azab N, Rady H, Marzouk S . Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol. 2012; 31(9):1359-64. DOI: 10.1007/s10067-012-2023-3. View

10.

Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M . Inhibition of trail gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes. Mol Pharmacol. 2007; 72(5):1246-57. DOI: 10.1124/mol.107.038042. View

11.

Mitsiades C, Treon S, Mitsiades N, Shima Y, Richardson P, Schlossman R . TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001; 98(3):795-804. DOI: 10.1182/blood.v98.3.795. View

12.

Chlichlia K, Moldenhauer G, Daniel P, Busslinger M, GAZZOLO L, Schirrmacher V . Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene. 1995; 10(2):269-77. View

13.

Wang Q, Zhou Y, Weiss H, Chow C, Evers B . NFATc1 regulation of TRAIL expression in human intestinal cells. PLoS One. 2011; 6(5):e19882. PMC: 3095616. DOI: 10.1371/journal.pone.0019882. View

14.

Emery J, McDonnell P, Burke M, Deen K, Lyn S, SILVERMAN C . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273(23):14363-7. DOI: 10.1074/jbc.273.23.14363. View

15.

Lin C, Wei W, Zhang J, Liu S, Liu Y, Zheng D . Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity. Mol Cancer Ther. 2007; 6(10):2618-25. DOI: 10.1158/1535-7163.MCT-07-0286. View

16.

Pan G, Ni J, Wei Y, Yu G, Gentz R, Dixit V . An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997; 277(5327):815-8. DOI: 10.1126/science.277.5327.815. View

17.

Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin K, Jeremias I . TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene. 2003; 22(25):3842-52. DOI: 10.1038/sj.onc.1206520. View

18.

Secchiero P, Gonelli A, Corallini F, Ceconi C, Ferrari R, Zauli G . Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis. 2010; 211(1):333-6. DOI: 10.1016/j.atherosclerosis.2010.02.024. View

19.

Ghaffari S, Jagani Z, Kitidis C, Lodish H, Khosravi-Far R . Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A. 2003; 100(11):6523-8. PMC: 164479. DOI: 10.1073/pnas.0731871100. View

20.

Schoppet M, Sattler A, Schaefer J, Hofbauer L . Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis. 2005; 184(2):446-7. DOI: 10.1016/j.atherosclerosis.2005.10.028. View